Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Neoadjuvant HAIC Combined With Tislelizumab and Lenvatinib in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model: a Multicenter Randomized Controlled Trial.

NCT06420440 is registered in ClinicalTrials.gov with Chen Xiaoping as lead sponsor.

NCT NCT06420440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06420440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Neoadjuvant HAIC Combined With Tislelizumab and Lenvatinib in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model: a Multicenter Randomized Controlled Trial.
Lead sponsor
Chen Xiaoping
Phase
Phase 2
Overall status
Recruiting
Start date
June 1, 2024
Completion date
May 31, 2027
Enrollment
160 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hcc